Equities

Futura Medical PLC

FUM:LSE

Futura Medical PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1.28
  • Today's Change0.0000000000000002 / 0.00%
  • Shares traded1.92m
  • 1 Year change-91.56%
  • Beta2.3019
Data delayed at least 20 minutes, as of Feb 06 2026 16:37 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Futura Medical plc is a consumer healthcare company that specializes in the development and global commercialization of sexual health products. The Company is a developer of sexual health products, including the lead product, Eroxon, and two products in development, including WSD4000 and Eroxon Intense. Eroxon is a clear gel used for the treatment of erectile dysfunction (ED) available over the counter and without prescription and addresses significant unmet needs in the ED market. Eroxon Intense provides a potential range extension of the Eroxon product and acts as an additional treatment option for men who have ED. WSD4000 is a topical treatment designed for sexual dysfunction in women. The Company has distribution partners in place in a number of major consumer markets, including Haleon in the United States, and Cooper Consumer Health in Europe.

  • Revenue in GBP (TTM)7.93m
  • Net income in GBP-6.29m
  • Incorporated2001
  • Employees12.00
  • Location
    Futura Medical PLC40 Occam RoadGUILDFORD GU2 7YGUnited KingdomGBR
  • Phone+44 14 8368 5670Fax+44 14 8368 5671
  • Websitehttps://www.futuramedical.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Roquefort Therapeutics PLC0.00-882.45k1.96m1.001.96m1.00
ValiRx Plc49.78k-1.78m2.56m14.002.56m14.00
N4 Pharma PLC7.07k-1.07m3.95m4.003.95m4.00
TheraCryf PLC0.00-2.01m4.51m9.004.51m9.00
Ovoca Bio PLC0.0065.12k5.28m1.005.28m1.00
Cizzle Biotechnology Holdings PLC0.00-1.12m6.14m67.006.14m67.00
Futura Medical PLC7.93m-6.29m7.41m12.007.41m12.00
OptiBiotix Health PLC1.15m-191.00k7.90m5.007.90m5.00
IXICO PLC6.53m-1.65m9.50m79.009.50m79.00
Genflow Biosciences PLC0.00-1.80m10.36m5.0010.36m5.00
Solvonis Therapeutics PLC0.00-2.60m17.02m--17.02m--
Fusion Antibodies PLC1.60m-1.47m20.00m24.0020.00m24.00
Sareum Holdings Plc0.00-4.44m23.47m5.0023.47m5.00
Data as of Feb 06 2026. Currency figures normalised to Futura Medical PLC's reporting currency: UK Pound GBX

Institutional shareholders

32.89%Per cent of shares held by top holders
HolderShares% Held
Lombard Odier Asset Management (Europe) Ltd.as of 12 Jan 202663.73m10.97%
Janus Henderson Investors UK Ltd.as of 01 Oct 202528.77m4.95%
UBS Asset Management (UK) Ltd.as of 01 Oct 202527.26m4.69%
Cantor Fitzgerald Europeas of 26 Dec 202525.57m4.40%
Lombard Odier Asset Management (USA) Corp.as of 01 Oct 202510.71m1.84%
Chelverton Asset Management Ltd.as of 31 Mar 20238.81m1.52%
Hargreaves Lansdown Fund Managers Ltd.as of 01 Oct 20258.08m1.39%
Atlantis Investment Management Ltd. /Hong Kong/as of 21 Apr 20217.94m1.37%
Unicorn Asset Management Ltd.as of 01 Oct 20255.75m0.99%
Maitland Asset Management (Pty) Ltd.as of 01 Oct 20254.50m0.77%
More ▼
Data from 31 Dec 2024 - 02 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.